



PATENT
ATTY. DOCKET NO.: MBM1240

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Zhu et al. Art Unit: 1645

Serial No.: 09/927,110 Examiner: Unassigned

Filed: August 20, 2001

Title: METHOD FOR INHIBITING INFLAMMATION IN IMMUNE
PRIVILEGED SITES USING FAS LIGAND FRAGMENTS

RECEIVED

Box Sequence

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

APR 01 2002

TECH CENTER 1600/2900

STATEMENT UNDER 37 C.F.R. §§ 1.821(f) and (g)

Sir:

I hereby state, as required by 37 C.F.R. § 1.821(f), that the information recorded in computer readable form is identical to the written sequence listing.

I hereby state that the submission, filed in accordance with 37 C.F.R. § 1.821 (g), herein does not include new matter.

Respectfully submitted,

Date: February 21, 2002

By: Richard T. Innes Reg. No. 37,643
Kelly Reynolds
Reg. No. P51,154
Telephone: (858) 638-6724
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92121-2133

Customer Number: 28213

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, <u>February 21, 2002</u> , in an envelope addressed to: U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327, Arlington, VA 22202.	
Mikhail Bayley	
Name of Person Mailing Paper	February 21, 2002
<i>Mikhail Bayley</i>	Date
Signature	



PATENT
ATTY. DOCKET NO.: MBM1240

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Zhu et al.

Art Unit: 1645

Serial No.: 09/927,110

Examiner: Unassigned

Filed: August 20, 2001

Title: METHOD FOR INHIBITING INFLAMMATION IN IMMUNE
PRIVILEGED SITES USING FAS LIGAND FRAGMENTS

RECEIVED

APR 01 2002

Box Sequence

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

TECH CENTER 1600/2900


VERIFIED STATEMENT UNDER 37 C.F.R. § 1.821(f)

Sir:

I, Mikhail Bayley, declare that I personally prepared the paper and the computer-readable copies of the Sequence Listing filed herewith in the above-entitled case and that the content of both is the same.


I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of The United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


Date: 02/21/2002


Mikhail Bayley

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92121-2133

Customer Number: 28213

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, <u>February 21, 2002</u> , in an envelope addressed to: U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327, Arlington, VA 22202.	
Mikhail Bayley	
Name of Person Mailing Paper	February 21, 2002
	Date
Signature	



SEQUENCE LISTING

<110> SEABRIGHT CORPORATION LIMITED
ZHU, Bing
CYNADER, Max
PATY, Donald
LUO, Liqing

<120> METHOD FOR INHIBITING INFLAMMATION IN IMMUNE PRIVILEGED SITES USING
FAS LIGAND FRAGMENTS

<130> MBM1240

<140> US 09/927,110
<141> 2001-08-10

<150> US 60/224,016
<151> 2000-08-10

<160> 1

<170> PatentIn version 3.0

<210> 1
<211> 281
<212> PRT
<213> Homo sapiens

<400> 1

Met Gln Gln Pro Phe Asn Tyr Pro Tyr Pro Gln Ile Tyr Trp Val Asp
1 5 10 15

Ser Ser Ala Ser Ser Pro Trp Ala Pro Pro Gly Thr Val Leu Pro Cys
20 25 30

Pro Thr Ser Val Pro Arg Arg Pro Gly Gln Arg Arg Pro Pro Pro Pro
35 40 45

Pro Pro Pro Pro Pro Leu Pro Pro Pro Pro Pro Pro Pro Pro Leu Pro
50 55 60

Pro Leu Pro Leu Pro Pro Leu Lys Lys Arg Gly Asn His Ser Thr Gly
65 70 75 80

Leu Cys Leu Leu Val Met Phe Phe Met Val Leu Val Ala Leu Val Gly
85 90 95

Leu Gly Leu Gly Met Phe Gln Leu Phe His Leu Gln Lys Glu Leu Ala
100 105 110

Glu Leu Arg Glu Ser Thr Ser Gln Met His Thr Ala Ser Ser Leu Glu
115 120 125

Lys Gln Ile Gly His Pro Ser Pro Pro Pro Glu Lys Lys Glu Leu Arg
130 135 140

Lys Val Ala His Leu Thr Gly Lys Ser Asn Ser Arg Ser Met Pro Leu
145 150 155 160

Glu Trp Glu Asp Thr Tyr Gly Ile Val Leu Leu Ser Gly Val Lys Tyr
165 170 175

RECEIVED
APR 01 2002
TECH CENTER 1600/2900

Lys Lys Gly Gly Leu Val Ile Asn Glu Thr Gly Leu Tyr Phe Val Tyr
180 185 190

Ser Lys Val Tyr Phe Arg Gly Gln Ser Cys Asn Asn Leu Pro Leu Ser
195 200 205

His Lys Val Tyr Met Arg Asn Ser Lys Tyr Pro Gln Asp Leu Val Met
210 215 220

Met Glu Gly Lys Met Met Ser Tyr Cys Thr Thr Gly Gln Met Trp Ala
225 230 235 240

Arg Ser Ser Tyr Leu Gly Ala Val Phe Asn Leu Thr Ser Ala Asp His
245 250 255

Leu Tyr Val Asn Val Ser Glu Leu Ser Leu Val Asn Phe Glu Glu Ser
260 265 270

Gln Thr Phe Phe Gly Leu Tyr Lys Leu
275 280
